Tau Phosphorylation Changes Across Lifespan in Down Syndrome and Alzheimer Disease

Overview

This study quantified tau phosphorylation at epitopes pThr181, pThr217, and pThr231 in frontal cortex tissue from individuals with Down syndrome (DS) and late-onset Alzheimer disease (LOAD). Findings reveal that tau pathology burdens increase with age in DS, paralleling LOAD, with DS showing earlier and more rapid accumulation of phosphorylated tau. These results enhance understanding of tau pathology progression in DS and its relationship to AD neuropathology.

Background

Individuals with Down syndrome have a heightened risk of developing Alzheimer disease due to chromosome 21 triplication and APP gene overexpression, leading to early amyloid beta accumulation typically after age 30. Neurofibrillary tangles composed of hyperphosphorylated tau appear later but progress rapidly in DS compared to late-onset AD. Biomarkers of phosphorylated tau in cerebrospinal fluid and plasma, including pThr181, pThr217, and pThr231, are emerging tools for early detection of AD pathology in DS. Understanding tau phosphorylation changes in brain tissue across the DS lifespan can inform biomarker development and disease staging.

Data Highlights

Key Findings

• LOAD and DSAD groups showed similar burdens of phosphorylated tau at pThr181, pThr217, and pThr231 epitopes in frontal cortex tissue.
• DSAD cases exhibited significantly higher p-tau burdens compared to young DS and age-matched neurotypical controls.
• Phosphorylated tau burdens increased with age in DS, demonstrating a differential age-associated rise across the lifespan.
• The progression of tau pathology in DS follows a Braak staging pattern similar to LOAD but occurs earlier and more rapidly.
• Immunohistochemical quantification using digital pathology provided reproducible measures of p-tau burden, encompassing pretangles, neurofibrillary tangles, neuropil threads, and dystrophic neurites.

Clinical Implications

These findings underscore the importance of monitoring tau phosphorylation biomarkers in individuals with Down syndrome for early detection and staging of Alzheimer disease pathology. The accelerated tau pathology progression in DS suggests that interventions targeting tau phosphorylation may need to be initiated earlier than in typical AD. Quantitative neuropathological assessment of p-tau epitopes can complement biofluid biomarker studies to improve diagnostic accuracy and therapeutic timing.

Conclusion

Tau phosphorylation at key epitopes increases with age in Down syndrome, paralleling but occurring earlier than in late-onset Alzheimer disease. This enhanced understanding of tau pathology progression in DS supports the use of p-tau biomarkers for early diagnosis and intervention.

References

1. Original Study -- Assessing Tau Phosphorylation Changes Throughout the Lifespan in Individuals with Down Syndrome